This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Tempur-Pedic Makes Donation To Pancreatic Cancer Action Network® At 2013 Las Vegas Market

LEXINGTON, Ky., Jan. 29, 2013 /PRNewswire/ --  Tempur-Pedic International Inc. (NYSE: TPX), a leading manufacturer, marketer and distributor of premium mattresses and pillows worldwide, made a special donation to the Pancreatic Cancer Action Network at the 2013 Las Vegas Market on behalf of the first 250 show attendees who participated in a Tempur-Pedic ® Rest Test of its expanded line of luxurious new mattress products, displayed in showroom C-1512.  


Attendees were invited to take a Rest Test and try the company's newest product innovations. On behalf of Rest Test participants, Tempur-Pedic made an additional donation of $12,500 to the Pancreatic Cancer Action Network in a check ceremony as part of its 2012 total donation of $200,000

Tempur-Pedic has a long history of supporting the Pancreatic Cancer Action Network and its comprehensive approach to fighting pancreatic cancer through research, providing vital patient support, community outreach and advocacy for a cure. To date, the company has raised more than $1.25 million, in part to help fund four research grants. 

"Through our ongoing Tempur-Pedic Hugs Back campaign, we've enjoyed the privilege of working with the Pancreatic Cancer Action Network for many years. In 2013, we remain dedicated to supporting the network and plan to continue bolstering it in any way possible by working with our retailers and our organization, starting with this donation at the Las Vegas Market trade show," said Rick Anderson, president of Tempur-Pedic North America. 

"Tempur-Pedic has had a tremendous impact on our organization and we are extremely grateful for their ongoing support and dedication to this cause," added Julie Fleshman, president and CEO, Pancreatic Cancer Action Network.

Making a Difference in Battling Pancreatic Cancer

On Jan. 2, President Obama signed into law the Recalcitrant Cancer Research Act, formerly the Pancreatic Cancer Research and Education Act. The landmark legislation requires the National Cancer Institute (NCI) to examine its current research efforts on cancers with very low survival rates and work to develop early detection methods and better treatment options to help improve outcomes for those diagnosed with the most deadly forms of cancer, including pancreatic and lung cancer.

This year alone, pancreatic cancer will claim more than 37,000 lives. At 6 percent, the disease has the lowest five-year survival rate of any major cancer, according to the Pancreatic Cancer Action Network. Passing of the legislation was a major victory in the fight against the disease made possible in part by the tireless efforts of the Pancreatic Cancer Action Network, its network of thousands of volunteers and advocates around the country, along with corporate donors such as Tempur-Pedic.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,813.39 +1.20 0.01%
S&P 500 2,088.87 -0.27 -0.01%
NASDAQ 5,116.1430 +13.3350 0.26%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs